NEW YORK, July 15, 2014 /PRNewswire/ -- According to BCC Research, the global market for women's health therapeutics is expected to reach $22.5 billion in 2018. Due to a variety of factors, such as an aging worldwide population, an increasing awareness among patients and physicians, the introduction of new therapies into the market, and the overall disease pattern and treatment differences between men and women, this market is expected to grow at a CAGR of 3.5% over the next five years.
TherapeuticsMD, Inc. (NYSEMKT: TXMD) is a specialty pharmaceutical company that focuses on women's healthcare products primarily related to pregnancy, childbirth, nursing, pre-menopause, menopause and post-menopause. Their current prescription and over-the-counter (OTC) dietary supplement and cosmetic product lines consist of prenatal vitamins, iron supplements, vitamin D supplements, natural menopause relief products and stretch mark creams, and are marketed under TXMD's vitaMedMD and BocaGreenMD brands. In addition, the company is also conducting clinical trials for hormone therapy pharmaceutical products that are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies such as hot flashes, osteoporosis and vaginal dryness.
If approved and commercialized, TXMD's hormone therapy drug candidates will allow the company to enter the $3.8 billion hormone therapy market. Within this overall market, TXMD estimates that the US market opportunity for a combination drug (estradiol and progesterone) is just north of $2 billion, while an estradiol-only drug and a progesterone-only drug operate in a market of around $1 billion and $360 million, respectively.
A full in-depth analyst report on TXMD that includes risk factors, industry review, financial position, potential revenues, review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link at no cost:
Copy and paste to browser may be required.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Michael Maggi, Chartered Financial Analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the full analyst report.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected]. For any urgent concerns or inquiries please contact us at [email protected].
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.